Seres Therapeutics Announces Presentation of Preliminary PK/PD and Safety Data for Investigational Microbiome Therapeutic SER-155 at ASH 2023
Seres Therapeutics, Inc. , a leading microbiome therapeutics company, announced today that preliminary clinical data from a currently enrolling Phase 1b study of SER-155 study in adult patients...
Memorial Sloan Kettering Cancer Center New York United States San Diego Convention Center San Diego Jonathan Peled
Source: marketscreener.com